A NON-INTERVENTIONAL, REGISTRY STUDY FOR CHINESE GASTRIC CANCER PATIENTS WITH HER2 STATUS: CLINICAL AND PATHOLOGICAL CHARACTERISTICS, TREATMENT PATTERNS AND CLINICAL OUTCOMES
N/A
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Both
Gastric Cancer
Both
Gastric Cancer
Trial Information
A NON-INTERVENTIONAL, REGISTRY STUDY FOR CHINESE GASTRIC CANCER PATIENTS WITH HER2 STATUS: CLINICAL AND PATHOLOGICAL CHARACTERISTICS, TREATMENT PATTERNS AND CLINICAL OUTCOMES
Inclusion Criteria:
- Histologically confirmed cancer of the stomach or gastro-oesophageal junction or
recurrent disease within 6 months before the date of recruitment
- Documented patient with trackable medical records
- HER2 IHC status is known
- Cohort I/II/IV:
Patients with mGC: with recurrent or metastatic disease or with inoperable locally
advanced disease
- Cohort III/V:
Patients with operable non-mGC: TxNxM0 (according to AJCC edition 7th)
Exclusion Criteria:
- Patients receiving regimen in a blinded trial
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Overall survival, defined as time from date of diagnosis of gastric cancer to death of any cause
Outcome Time Frame:
up to 5 years
Safety Issue:
No
Principal Investigator
Clinical Trials
Investigator Role:
Study Director
Investigator Affiliation:
Hoffmann-La Roche
Authority:
China: Food and Drug Administration
Study ID:
ML28934
NCT ID:
NCT01839500
Start Date:
April 2013
Completion Date:
April 2018
Related Keywords:
- Gastric Cancer
- Stomach Neoplasms
Name | Location |
|---|
